Construction method of standardized evaluation model for repeated medication of Chinese patent medicine

Abstract

The invention provides a construction method of a Chinese patent medicine repeated medication standardization evaluation model. The construction method of the Chinese patent medicine repeated medication standardization evaluation model comprises the following steps: S1, acquiring diagnosis and treatment details of a patient, and identifying a specification of Chinese patent medicines recorded in the diagnosis and treatment details; and S2, inspecting whether the indications among the medicines are the same or similar according to the specification information. According to the construction method of the Chinese patent medicine repeated medication standardization evaluation model, whether indications are repeated or not, whether prescription medicines are repeated or not and whether the prescription medicines are in the same efficacy classification or not are investigated one by one, particularly, weighting processing of special components is emphasized, and all results are included for comprehensive evaluation; according to the method, the Chinese patent medicines with high safety risk, which contain toxic and strong decoction pieces or chemical components, can be strictly managed and controlled, and the Chinese patent medicines with different formula ideas for treating the same indication can be flexibly treated in a combined manner, so that the scientificity of comment is improved.

Description

Technical Field

[0001] The present invention relates to the medical field, and in particular to a method for constructing a standardized evaluation model for repeated use of Chinese patent medicines. Background Art

[0002] Chinese patent medicines are Chinese medicinal materials that are processed into certain dosage forms according to prescribed prescriptions and preparation processes under the guidance of traditional Chinese medicine theory for the purpose of preventing and treating diseases. They are a type of commercialized Chinese medicine preparations approved by drug supervision and administration departments. Therefore, as Chinese patent medicines for clinical use, they must not only have corresponding drug names, usage and dosage, specifications, specific quality standards and inspection methods, but also have definite efficacy, clear scope of application, application contraindications and precautions.

[0003] However, clinical medication often involves the combined use of Chinese patent medicines with similar efficacy and ingredients (for example, Quick-acting Heart-saving Pills and Compound Danshen Drops, Lanqin Oral Liquid and Pueraria Anti-inflammatory Granules, etc.). Therefore, repeated use of medicines is the primary issue to be considered in the combined use of Chinese patent medicines, but there is currently a lack of objective evaluation methods.

[0004] Therefore, it is necessary to provide a method for constructing a standardized evaluation model for repeated use of traditional Chinese medicines to solve the above technical problems. Summary of the invention

[0005] The present invention provides a method for constructing a standardized evaluation model for repeated use of Chinese patent medicines, which solves the problem of the current lack of an objective evaluation method for repeated use of Chinese patent medicines.

[0006] In order to solve the above technical problems, the present invention provides a method for constructing a standardized evaluation model for repeated use of Chinese patent medicines, comprising the following steps:

[0007] S1: Obtain the patient's diagnosis and treatment details and identify the instructions for the Chinese patent medicines recorded in the diagnosis and treatment details;

[0008] S2: Based on the information in the instructions, examine whether the indications of the drugs are the same or similar;

[0009] S3: According to the information in the instructions, the number of identical medicinal flavors among the drug compositions was investigated;

[0010] S4: Based on authoritative reference materials, examine whether the drugs belong to the same efficacy category;

[0011] S5: Based on the information in the instructions, examine whether the drug formulas contain the same toxic or potent herbal pieces or chemical drug components;

[0012] S6: Number of drugs with duplicate information in any of the above items;

[0013] S7: Whether the drugs involved in any of the above duplicate information are administered by the same route;

[0014] S8: Collect the above information to determine whether there is any duplication of medication.

[0015] By examining whether the indications are repeated one by one, examining whether the prescriptions are repeated, and especially examining whether the special components are in the same efficacy classification, all results are included in the comprehensive evaluation, which can not only strictly control the Chinese patent medicines containing toxic, strong pieces of medicine or chemical components with higher safety risks, but also flexibly deal with the combination of Chinese patent medicines with different formulation ideas for the same indication, thereby improving the scientific nature of the review;

[0016] In S4, authoritative works such as "Chinese Pharmacopoeia Clinical Medication Instructions·Chinese Medicine Formula Preparation Volume", "Guidelines for Clinical Application of Chinese Patent Medicines", and "Beijing Basic Medical Insurance Drug Catalog" can be used as reference classification standards; for example, the combination of Biaoshi Ganmao Granules and Fenghan Ganmao Granules, both of which belong to the category of pungent and warm relieving exterior symptoms, is considered repeated medication;

[0017] Preferably, the S2 is reviewed based on the functional descriptions in the instructions for use of the Chinese patent medicine, and if they are completely consistent, it is considered to be repeated use of the medicine.

[0018] Preferably, the S2 is commented on based on the description of the main indications in the instructions for the Chinese patent medicine, which are completely or basically consistent, and thus constitute repeated use of the medicine.

[0019] Preferably, the combined use of Chinese patent medicines with the same medicinal flavor in different dosage forms and from different manufacturers in S3 constitutes repeated medication.

[0020] Preferably, the method further comprises: S1, examining whether the indications of the drugs are the same or similar according to the instructions, and if they are the same or similar, 1 point is given;

[0021] S2. According to the information in the instructions, the number of identical medicinal ingredients in the drug composition was examined and classified into: no duplication, 1-2 duplications, 3-5 duplications, and more than 5 duplications, and different scores were given;

[0022] S3. Based on authoritative reference materials, examine whether the drugs belong to the same efficacy category. If not, no points will be awarded. If yes, 1 point will be awarded.

[0023] S4. According to the information in the instructions, examine whether the drug formulas contain the same toxic or strong medicinal pieces or chemical drug components. If not, no points will be awarded. If yes, 2 points will be awarded.

[0024] S5. The number of drugs involved in any of the above repeated information: no points if none, 1 point if two, 2 points if three or more;

[0025] S6. Whether the drugs involved in any of the above repeated information are administered by the same route. If not, deduct 1 point. If yes, deduct 1 point. If yes and it includes intravenous administration, deduct 2 points.

[0026] S7. Finally, the standard threshold was set to 4 points, and the total score of the S1, S2, S3, S4, S5 and S6 indicators was calculated.

[0027] Preferably, if there is no repetition in S2, 1 point will be deducted, if 1-2 flavors are repeated, no points will be given, if 3-5 flavors are repeated, 1 point will be given, and if more than 5 flavors are repeated, 2 points will be given.

[0028] Preferably, if the score in S7 is less than 4, it is not considered as repeated use of medication.

[0029] Preferably, a score of 4-8 in S7 is considered as repeated medication, and a score of 8 or more is considered as severe repeated medication.

[0030] Preferably, it also includes: reduced use of Chinese patent medicines and excessive use of Chinese patent medicines.

[0031] Preferably, if the dosage of the Chinese patent medicine is reduced to more than 30% of the dosage for the corresponding age group in the instructions, 1 point will be deducted from the total score; if the Chinese patent medicine is used in excess, exceeding the dosage for the corresponding age group in the instructions by more than 30%, 1 point will be added to the total score.

[0032] Compared with the related art, the method for constructing a standardized evaluation model for repeated use of Chinese patent medicines provided by the present invention has the following beneficial effects:

[0033] The invention provides a method for constructing a standardized evaluation model for repeated use of Chinese patent medicines. The method comprises the following steps: obtaining the diagnosis and treatment details of a patient and identifying the instructions of the Chinese patent medicines recorded in the diagnosis and treatment details; examining whether the indications between the medicines are the same or similar according to the instructions information; examining the number of the same medicinal flavors between the medicine compositions according to the instructions information; and examining whether the medicines belong to the same efficacy category according to authoritative reference materials; examining whether the medicine prescriptions contain the same toxic or strong medicinal pieces or chemical medicine components according to the instructions information; and the number of medicines involving any of the repeated information above; and whether the medicines involving any of the repeated information above are for the same route of administration; and finally counting the above information to determine whether there is repeated use of medicines. By examining whether the indications are repeated, whether the medicinal flavors of the prescriptions are repeated, and whether they are in the same efficacy category one by one, the weighted processing of special components is particularly emphasized, and all results are included for comprehensive evaluation. The method can strictly control Chinese patent medicines containing toxic or strong medicinal pieces or chemical components with higher safety risks, and can flexibly handle the combined use of Chinese patent medicines with different formulation ideas for treating the same indication, thereby improving the scientific nature of the evaluation. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Figure 1A schematic diagram of the steps of the method for constructing a standardized evaluation model for repeated use of Chinese patent medicines provided by the present invention;

[0035] Figure 2 A schematic diagram of the evaluation steps of the method for constructing a standardized evaluation model for repeated use of Chinese patent medicines provided by the present invention.

[0036] Figure 3 An information self-checking system for the construction method of the standardized evaluation model for repeated use of Chinese patent medicines provided by the present invention;

[0037] Figure 4 This is a schematic diagram of the information self-checking system analysis structure of the method for constructing a standardized evaluation model for repeated use of traditional Chinese medicines provided by the present invention. DETAILED DESCRIPTION

[0038] The present invention will be further described below in conjunction with the accompanying drawings and implementation modes.

[0039] Please refer to Figure 1 , Figure 2 , Figure 3 and Figure 4 ,in, Figure 1 A schematic diagram of the steps of the method for constructing a standardized evaluation model for repeated use of Chinese patent medicines provided by the present invention; Figure 2 A schematic diagram of the evaluation steps of the method for constructing a standardized evaluation model for repeated use of Chinese patent medicines provided by the present invention; Figure 3 An information self-checking system for the construction method of the standardized evaluation model for repeated use of Chinese patent medicines provided by the present invention; Figure 4 The schematic diagram of the information self-checking system analysis structure of the method for constructing a standardized evaluation model for repeated use of Chinese patent medicines provided by the present invention. The method for constructing a standardized evaluation model for repeated use of Chinese patent medicines comprises the following steps:

[0040] S1: Obtain the patient's diagnosis and treatment details and identify the instructions for the Chinese patent medicines recorded in the diagnosis and treatment details;

[0041] S2: Based on the information in the instructions, examine whether the indications of the drugs are the same or similar;

[0042] S3: According to the information in the instructions, the number of identical medicinal flavors among the drug compositions was investigated;

[0043] S4: Based on authoritative reference materials, examine whether the drugs belong to the same efficacy category;

[0044] S5: Based on the information in the instructions, examine whether the drug formulas contain the same toxic or potent herbal pieces or chemical drug components;

[0045] S6: Number of drugs with duplicate information in any of the above items;

[0046] S7: Whether the drugs involved in any of the above duplicate information are administered by the same route;

[0047] S8: Collect the above information to determine whether there is any duplication of medication.

[0048] By examining whether the indications are repeated and whether the prescriptions are repeated, the current status of repeated use of Chinese patent medicines is sorted out, and the core elements used to assist in the evaluation scale are extracted. In particular, for special components, whether they are in the same efficacy classification is examined, and all results are included for comprehensive evaluation. This can not only strictly control Chinese patent medicines containing toxic, potent pieces or chemical components with higher safety risks, but also flexibly deal with the combination of Chinese patent medicines with different formulation ideas for the same indication, thereby improving the scientific nature of the evaluation;

[0049] Evaluation based on the contents of the instructions (functions and indications): This type of review focuses on the comparison of the information in the "functions and indications" section of the instructions. First, the review is based on the description of the "function" section of the instructions for Chinese patent medicines. If they are completely consistent, it is considered to be repeated use of the medicine, such as the combination of Ganmao Qingre Granules and Ganmao Qingre Capsules, the combination of Huoxue Tongmai Capsules and Naoxuekang Oral Liquid, etc.; Second, the review is based on the description of the "indications" section of the instructions for Chinese patent medicines (including TCM diseases and Western medicine diseases). If they are completely consistent or basically consistent, it is considered to be repeated use of the medicine, such as the combination of Fufang Danshen Dripping Pills and Suxiao Jiuxin Pills, and the combination of Shuanghuanglian Capsules and Pudilan Xiaoyan Capsules;

[0050] Evaluation based on the composition of the medicinal ingredients in the instructions: This type of review focuses on the comparison of the "ingredients" item in the instructions; first, the combination of Chinese patent medicines with the same medicinal ingredients in different dosage forms and from different manufacturers is considered repeated use of medicines; second, when one part of the formula is the same and the other part is different, such as some medical institutions use repeated medicinal ingredients as the basis to determine the combination of Qiangshen Tablets and Wengbi Granules, and the combination of Baizi Yangxin Pills and Qiju Dihuang Pills as repeated use of medicines; while some medical institutions will add additional conditions such as the percentage of repeated medicinal ingredients, whether it is toxic, and whether it is the main drug, and make a comprehensive review; for example, the combination of Yindan Xinnaotong Soft Capsules (Ginkgo biloba as the main drug) and Ginkgo biloba tablets is considered repeated use of medicines, while the combination of Yindan Xinnaotong Soft Capsules (Hawthorn as the adjuvant drug) and Dashanzha Pills is not considered repeated use of medicines;

[0051] Evaluation based on the efficacy category of Chinese patent medicines: This type of review focuses on whether the Chinese patent medicines used in combination belong to the same efficacy category; that is, it emphasizes that the judgment is made based solely on the efficacy category information, that is, "whether they belong to the same category"; authoritative works such as "Chinese Pharmacopoeia Clinical Drug Use Instructions·Chinese Herbal Formula Preparation Volume", "Guidelines for the Clinical Application of Chinese Patent Medicines", and "Beijing Basic Medical Insurance Drug Catalog" are reference classification standards; for example, the combination of Biaoshi Ganmao Granules and Fenghan Ganmao Granules, which both belong to the category of pungent and warm relieving exterior symptoms, is considered repeated use of drugs;

[0052] Evaluation based on the derivative relationship between Chinese patent medicines: This type of review focuses on whether there is a derivative relationship between Chinese patent medicines; the most classic derivative prescription series is the Dihuang Pill series. A number of Dihuang Pills that are mainly used to nourish yin or yang are developed based on Liuwei Dihuang Pills. When used together, there is a high suspicion of repeated use of drugs, such as Zhibai Dihuang Pills and Qiju Dihuang Pills, Guifu Dihuang Pills and Jisheng Shenqi Pills, etc. In addition, the formulation characteristics of many Chinese patent medicines are simply added or subtracted from other Chinese patent medicines, and there is no significant difference in the main efficacy. Such drugs can also be regarded as derivative prescriptions for evaluation;

[0053] Evaluation of repeated use of toxic components: This type of review focuses on whether there are the same toxic components in the Chinese patent medicines used in combination; for example, the combination of Fugui Gutong Capsules and Qiangli Tianma Duzhong Capsules is considered repeated use because both contain aconite and monkshood; for another example, there are literature reports that the combination of Hulisan Capsules and Biqi Capsules is repeated use because Hulisan Capsules contain processed aconite and Biqi Capsules contain strychnine, and the combination of the two has a higher risk of adverse reactions; the safety of combined use is the focus of this type of evaluation;

[0054] Focus on the evaluation of repeated use of compound preparations of Chinese and Western medicines: This type of review focuses on the problem of repeated use of chemical components in compound preparations of Chinese and Western medicines; for example, the combination of Vitamin C Yinqiao Tablets and Compound Ganmaoling Tablets is considered repeated use because both contain acetaminophen and chlorpheniramine maleate; some scholars have summarized the common varieties of Chinese patent medicines containing Western medicines and found that the chemical drugs are mainly concentrated in 8 categories, including hypoglycemic drugs, antipyretic analgesics, antiallergic drugs, cough and antiasthmatic drugs, antihypertensive drugs, and antacids. They need to be used with extreme caution in clinical combination;

[0055] At the same time, an information self-inspection system can be set up based on the standardized evaluation model for repeated use of Chinese patent medicines. By selecting the name of the drug and whether the dosage is exceeded, self-service judgment can be made.

[0056] In S2, the functional descriptions of the Chinese patent medicine instructions are reviewed, and if they are completely consistent, it is considered to be repeated use of the medicine;

[0057] The S2 is commented on based on the description of the main indications in the instructions of the Chinese patent medicine, which are completely or basically the same, and constitute duplicate medication.

[0058] The combination of Chinese patent medicines with the same medicinal flavor but in different dosage forms and from different manufacturers in S3 is repeated medication.

[0059] It also includes: S1. Based on the information in the instructions, examine whether the indications of the drugs are the same or similar. If they are the same or similar, 1 point will be given;

[0060] S2. According to the information in the instructions, the number of identical medicinal ingredients in the drug composition was examined and classified into: no duplication, 1-2 duplications, 3-5 duplications, and more than 5 duplications, and different scores were given;

[0061] S3. Based on authoritative reference materials, examine whether the drugs belong to the same efficacy category. If not, no points will be awarded. If yes, 1 point will be awarded.

[0062] S4. According to the information in the instructions, examine whether the drug formulas contain the same toxic or strong medicinal pieces or chemical drug components. If not, no points will be awarded. If yes, 2 points will be awarded.

[0063] S5. The number of drugs involved in any of the above repeated information: no points if none, 1 point if two, 2 points if three or more;

[0064] S6. Whether the drugs involved in any of the above repeated information are administered by the same route. If not, deduct 1 point. If yes, deduct 1 point. If yes and it includes intravenous administration, deduct 2 points.

[0065] S7. Finally, the standard threshold was set to 4 points, and the total score of the S1, S2, S3, S4, S5 and S6 indicators was calculated.

[0066] If there is no repetition in S2, 1 point will be deducted; if 1-2 flavors are repeated, no points will be given; if 3-5 flavors are repeated, 1 point will be given; if more than 5 flavors are repeated, 2 points will be given.

[0067] If the score of S7 is less than 4, it is not considered as repeated use of medication.

[0068] A score of 4-8 in S7 is considered as duplication of medication, and a score of 8 or more is considered as severe duplication of medication.

[0069] It also includes: reduced use of Chinese patent medicines and excessive use of Chinese patent medicines.

[0070] If the dosage of the Chinese patent medicine is reduced to more than 30% of the dosage for the corresponding age group in the instructions, 1 point will be deducted from the total score. If the Chinese patent medicine is used in excess and exceeds 30% of the dosage for the corresponding age group in the instructions, 1 point will be deducted from the total score.

[0071] Prescription review that integrates all concerns is obviously more comprehensive, that is, the conditions for judging repeated medication should be combined. In other words, when judging whether there is repeated medication among multiple combined drugs, it is advisable to examine whether the indications are repeated, whether the prescription drug flavors are repeated (especially for special components), and whether they are in the same efficacy classification one by one, and include all results for comprehensive evaluation. This can not only strictly control Chinese patent medicines containing toxic or potent decoction pieces or chemical components with higher safety risks, but also flexibly handle the combination of Chinese patent medicines with different formulation ideas for the same indication, thereby improving the scientific nature of the review; based on the clinical review work, indicators used in the auxiliary evaluation scale were designed. In addition to the four core elements mentioned above, they also include the number of combined medications, the route of administration of combined medications, the number of repeated drug flavors, etc.; on this basis, six judgment conditions and review criteria for repeated medication of Chinese patent medicines were designed (see Table 1); according to the scale, a preliminary comprehensive evaluation of the repeated medication of Chinese patent medicines can be easily carried out:

[0072] Table 1 Standardized evaluation indicators for repeated use of Chinese patent medicines

[0073]

[0074] After the two Chinese patent medicines are used together, the scores of the above six indicators are judged one by one, and the total score is calculated. At the same time, if the Chinese patent medicine is used in a reduced dosage (reduced to more than 30% of the dosage for the corresponding age group in the instructions), the total score will be subtracted by 1 point; if the Chinese patent medicine is used in an excessive dosage (more than 30% of the dosage for the corresponding age group in the instructions), the total score will be added by 1 point;

[0075] A threshold of 4 points is set, and scores below 4 are not considered as duplicate medication; scores between 4 and 8 are considered as duplicate medication; and scores above 8 are considered as severe duplicate medication.

[0076] Validation of the Chinese patent medicine repeat medication auxiliary evaluation scale:

[0077] After the model was established, this group used common clinical repeated medication combinations and non-repeated medication combinations to verify the effectiveness and sensitivity of the scale; then, using Naoxintong Capsules, Tongxinluo Capsules, Suxiao Jiuxin Pills and Ganmao Qingre Granules as examples, the effectiveness and sensitivity of the auxiliary evaluation scale were analyzed;

[0078] Naoxintong Capsules (normal dosage) + Tongxinluo Capsules (normal dosage):

[0079] Naoxintong capsule is composed of astragalus, red peony root, salvia miltiorrhiza, angelica, chuanxiong, peach kernel, safflower, frankincense (processed), myrrh (processed), millettia, Achyranthes bidentata, cinnamon twig, mulberry twig, earthworm, scorpion, leech, and has the functions of invigorating qi and activating blood circulation, removing blood stasis and dredging collaterals. It is used for stroke meridians caused by qi deficiency and blood stasis, blood stasis in the meridians, hemiplegia, numbness of limbs, facial paralysis, tongue stiffness and dysphagia, as well as chest pain, chest tightness, palpitations, and shortness of breath; cerebral infarction, angina pectoris caused by coronary heart disease; Tongxinluo capsule is composed of ginseng, leech, scorpion, red peony root, cicada shell, earthworm, centipede, sandalwood, aloeswood, frankincense (processed), Ziziphus jujuba seeds (fried), and borneol, and has the functions of invigorating qi and activating blood circulation, dredging collaterals and relieving pain. It is used for Angina pectoris in coronary heart disease belongs to the syndrome of deficiency of heart qi and blood stasis and obstruction of collaterals, with symptoms of chest tightness, stabbing pain, colic, fixed pain, palpitations and spontaneous sweating, shortness of breath and fatigue, purple tongue or ecchymosis, thin and wiry pulse or intermittent pulse; it is also used for stroke caused by deficiency of qi, blood stasis and obstruction of collaterals, with symptoms of hemiplegia or numbness of one side of the body, crooked mouth and tongue, and slurred speech; it can be seen that both are not only qi-invigorating, blood-activating and blood-stasis-removing drugs, and both treat coronary heart disease caused by deficiency of qi and blood stasis, but also contain toxic Chinese medicines such as frankincense, scorpion and leech, and the medical insurance catalog is also under the same efficacy subcategory, so there is a high possibility of repeated use of the drugs; according to the calculation of this auxiliary evaluation scale, the score of the combined use of the two is 8 points, and repeated use is strongly recommended.

[0080] Naoxintong Capsules (normal dosage) + Suxiao Jiuxin Pills (overdose):

[0081] The information of Naoxintong Capsule is the same as before; Suxiao Jiuxin Pills are composed of Chuanxiong and borneol, which can promote qi and blood circulation, remove blood stasis and relieve pain, increase coronary blood flow, and relieve angina pectoris; it is used for coronary heart disease of qi stagnation and blood stasis type, and angina pectoris; therefore, Naoxintong Capsule and Suxiao Jiuxin Pills have similar and different effects. The similarity is that both of them can promote blood circulation and remove blood stasis, and the difference is that Naoxintong Capsule focuses on invigorating qi, while Suxiao Jiuxin Pills focus on promoting qi; however, the two do have one similar effect (promoting blood circulation and removing blood stasis) and one similar ingredient (Chuanxiong), and Suxiao Jiuxin Pills are used in doses beyond the instructions. In this case, the two may be duplicated; according to the calculation of this auxiliary evaluation scale, the score for the combined use of the two is 5 points, and it is recommended to be judged as duplicated; in fact, from a clinical point of view, unless Suxiao Jiuxin Pills are taken when necessary, the clinical significance of combined use is not obvious.

[0082] Naoxintong Capsules (normal dosage) + Ganmaoqingre Granules (normal dosage):

[0083] The information of Naoxintong Capsules is the same as before; Ganmaoqingre Granules are composed of Schizonepeta spicate, Menthus alba, Saposhnikovia divaricata, Bupleurum chinense, Perilla frutescens, Pueraria lobata, Platycodon grandiflorum, Apricot kernel, Angelica dahurica, Sophora flavescens, and Phragmites australis, and have the effects of dispelling wind and cold, relieving exterior symptoms and clearing heat, and are used for wind-cold colds, headaches and fevers, aversion to colds and body aches, clear nasal discharge, and coughs and dry throats; it can be seen that the two treat completely different diseases, one is used for coronary heart disease and the other for colds, and the two have no duplicate medicinal flavors, so the possibility that the two are repeated in combination is very small; according to the calculation of this auxiliary evaluation scale, the score for the combination of the two is 0, and it is not recommended to be judged as repeated medication.

[0084] The above descriptions are merely embodiments of the present invention and are not intended to limit the patent scope of the present invention. Any equivalent structure or equivalent process transformation made using the contents of the present invention specification and drawings, or directly or indirectly applied in other related technical fields, are also included in the patent protection scope of the present invention.

Claims

1. A method for constructing a standardized evaluation model for repeated use of Chinese patent medicines, characterized in that: The following steps are involved: S1: Obtain the patient's diagnosis and treatment details and identify the instructions for the Chinese patent medicines recorded in the diagnosis and treatment details; S2: Based on the information in the instructions, examine whether the indications of the drugs are the same or similar; S3: According to the information in the instructions, the number of identical medicinal flavors among the drug compositions was investigated; S4: Based on authoritative reference materials, examine whether the drugs belong to the same efficacy category; S5: Based on the information in the instructions, examine whether the drug formulas contain the same toxic or potent herbal pieces or chemical drug components; S6: Number of drugs with duplicate information in any of the above items; S7: Whether the drugs involved in any of the above duplicate information are administered by the same route; S8: Collect the above information to determine whether there is any duplication of medication.

2. The method for constructing a standardized evaluation model for repeated use of Chinese patent medicines according to claim 1, characterized in that: In the above S2, the functional descriptions of the Chinese patent medicine instructions are reviewed, and if they are completely consistent, it is considered to be repeated use of the medicine.

3. The method for constructing a standardized evaluation model for repeated use of Chinese patent medicines according to claim 1, characterized in that: The S2 is commented on based on the description of the main indications in the instructions of the Chinese patent medicine, which are completely or basically the same, and constitute duplicate medication.

4. The method for constructing a standardized evaluation model for repeated use of Chinese patent medicines according to claim 1, characterized in that: The combination of Chinese patent medicines with the same medicinal flavor but in different dosage forms and from different manufacturers in S3 is repeated medication.

5. The method for constructing a standardized evaluation model for repeated use of Chinese patent medicine according to any one of claims 1 to 4, characterized in that: Also includes: S1. Based on the information in the instructions, examine whether the indications of the drugs are the same or similar. If they are the same or similar, 1 point will be given; S2. According to the information in the instructions, the number of identical medicinal ingredients in the drug composition was examined and classified into: no duplication, 1-2 duplications, 3-5 duplications, and more than 5 duplications, and different scores were given; S3. Based on authoritative reference materials, examine whether the drugs belong to the same efficacy category. If not, no points will be awarded. If yes, 1 point will be awarded. S4. According to the information in the instructions, examine whether the drug formulas contain the same toxic or strong medicinal pieces or chemical drug components. If not, no points will be awarded. If yes, 2 points will be awarded. S5. The number of drugs involved in any of the above repeated information: no points if none, 1 point if two, 2 points if three or more; S6. Whether the drugs involved in any of the above repeated information are administered by the same route. If not, deduct 1 point. If yes, deduct 1 point. If yes and it includes intravenous administration, deduct 2 points. S7. Finally, the standard threshold was set to 4 points, and the total score of the S1, S2, S3, S4, S5 and S6 indicators was calculated.

6. The method for constructing a standardized evaluation model for repeated use of Chinese patent medicines according to claim 5, characterized in that: If there is no repetition in S2, 1 point will be deducted; if 1-2 flavors are repeated, no points will be given; if 3-5 flavors are repeated, 1 point will be given; if more than 5 flavors are repeated, 2 points will be given.

7. The method for constructing a standardized evaluation model for repeated use of Chinese patent medicines according to claim 5, characterized in that: If the score of S7 is less than 4, it is not considered as repeated use of medication.

8. The method for constructing a standardized evaluation model for repeated use of Chinese patent medicines according to claim 5, characterized in that: A score of 4-8 in S7 is considered as duplication of medication, and a score of 8 or more is considered as severe duplication of medication.

9. The method for constructing a standardized evaluation model for repeated use of Chinese patent medicines according to claim 5, characterized in that: Also includes: Reduced use of Chinese patent medicines and excessive use of Chinese patent medicines.

10. The method for constructing a standardized evaluation model for repeated use of Chinese patent medicines according to claim 9, characterized in that: If the dosage of the Chinese patent medicine is reduced to more than 30% of the dosage for the corresponding age group in the instructions, 1 point will be deducted from the total score. If the Chinese patent medicine is used in excess and exceeds 30% of the dosage for the corresponding age group in the instructions, 1 point will be deducted from the total score.

Images